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Quality of life (QOL) in patients with mental disor-
ders is an important issue when emphasizing a more
consumer-oriented and holistic view of health care [1].
QOL is defined as the individuals’ perceptions of their
life position in the context of the culture and value
systems in which they live, and in relation to their
goals, expectations, standards and concerns. QOL is a
complex and broad-ranging concept, incorporating an
individual’s physical health, psychological state, inde-
pendence level, social relations, personal beliefs, and
relationship to salient features of the environment [2].
The concept of QOL differs from that of disability or
impairment because different patients may react dif-
ferently to similar levels of disability or impairment
[3]. QOL has four uses in medicine: (1) for the plan-
ning of clinical care of individual patients; (2) as an
outcome measure in clinical trials and health services
research; (3) to assess the health needs of populations;
and (4) for resource allocation [4].
Obsessive-compulsive disorder (OCD) is a chronic
illness associated with a high potential for disability
[5,6]. OCD has a significant negative impact on pa-
tients’ social and family relationships [7–9], marital
relations [7,10], learning ability [9], occupational func-
tion [7–9,11] and self-esteem [7,9], as well as increasing
the risk of depression [8], suicidality [7], and alcohol
and illicit drug abuse [7]. Previous studies have found
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The care of patients with obsessive-compulsive disorder (OCD) has raised quality of life (QOL)
issues. The purpose of this study was to compare the level of QOL between patients with and
without OCD, and to examine the associations between QOL and sociodemographic data, course
of illness, psychopathology, perceived social support, and treatment characteristics. The QOL
levels measured with the Taiwan version of the Short Form of the World Health Organization
Questionnaire on Quality of Life were compared between 57 subjects with OCD and 106 subjects
without OCD. The correlates of QOL were examined among subjects with OCD. The analysis
revealed that QOL scores for the general, physical, psychological and social relationship domains
were lower in the OCD group than in the control group; however, no difference in the environ-
mental domain was found. Multiple factors were associated with poor QOL in subjects with
OCD, including comorbid depression, severe obsession symptoms, perceived low social support,
severe adverse effects of medication, combined use of mood stabilizers, and low social status.
Different domains of QOL are differently affected by OCD. The QOL of subjects with OCD was
correlated to multiple factors that were specific to individual subjects and influenced by interac-
tions with treatment and the social environment.
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that QOL was worse among patients with OCD than
in the general population [12], or patients with de-
pressive disorders [12], heroin dependence [12], social
phobia [13], panic disorder [13] and type 2 diabetes
mellitus [8]. As assessing the impact of OCD on QOL
is an important aid to make decisions on how aggres-
sively the disorder should be treated for an outcome
measure, for health needs assessments of patients and
for resource allocation [4], further studies are needed
to examine the correlates of QOL and to develop
effective strategies to improve the QOL in patients
with OCD.
To date, few studies have examined the factors that
influence QOL in patients with OCD. Previous studies
have found that severe OCD symptoms and comorbid
depression were associated with poor QOL in patients
with OCD [8,13]. Antidepressant treatment was also
found to improve the QOL of OCD patients [8,14].
However, patients with anxiety disorders might per-
ceive the adverse effects of antidepressants, which can
result in low medical adherence [15]. Furthermore,
the adverse effects of medications negatively impact
on some QOL domains of patients with panic disor-
ders [16], depressive disorders [17], bipolar disorder
[18] and schizophrenia [18]. However, little is known
about the impact of adverse effects of pharmacother-
apy on QOL in patients with OCD. Although selective
serotonin reuptake inhibitors are first-line medications
and other antidepressants, e.g. clomipramine, seroto-
nin norepinephrine reuptake inhibitors and mono-
amine oxidase inhibitors are second-line medications
for OCD, patients who have been unsuccessfully
treated with several antidepressants are often asked to
consider augmentation of selective serotonin reuptake
inhibitors with an antipsychotic or a mood stabilizer
[19]. The influence of augmentation by antipsychotics
or mood stabilizers on the QOL of patients with OCD
needs further studies.
Previous studies have found that social support can
reduce the impact of chronic stress on psychological
well-being [20] and improved QOL in patients with
severe mental [21–23] and chronic medical illnesses
[24,25]. However, the relationship between QOL and
social support in patients with OCD is still unknown.
Further studies are needed to examine the impact of
sociodemographic characteristics and course of illness
on QOL in patients with OCD.
The aims of this study were (1) to examine whether
different domains of QOL are differently affected by
OCD by comparing the QOL of subjects with and
without OCD; and (2) to examine the association of
QOL with sociodemographic characteristics (sex, age,
education level, marriage status, social status and
attending religious activities), course of illness (onset
age and duration of illness), psychopathology (sever-
ities of depression, obsession and compulsion), per-
ceived social support, and treatment characteristics
(adverse effects of medication and variety of medica-
tion) among subjects with OCD.
METHODS
Subjects
From February to November 2008, 65 patients with
OCD were consecutively recruited from the outpatient
psychiatric clinics at a medical center and a regional
teaching hospital in Southern Taiwan. Of these, five
patients (3 men and 2 women) refused to participate
in this study. Of the 60 patients who agreed to join the
study, 57 patients who had received medication for
OCD in the preceding 2 weeks were included in the
study; the three patients who did not receive medica-
tion were not included. A psychiatrist systematically
assessed all patients to confirm the diagnosis of OCD
using the structured Mini-International Neuropsychia-
tric Interview [26] based on the diagnostic schemes of
the 4th edition of the Diagnostic and Statistical Manual
of Mental Disorders [27].
To recruit subjects for the control group, we posted
an advertisement in the hospital and in newspapers to
invite participation. A total of 157 persons responded
to the advertisement. A psychiatrist assessed all res-
ponders systematically to determine whether they
had any mood or psychotic disorders using the Mini-
International Neuropsychiatric Interview [26]. Those
who had OCD, mood disorders, psychotic disorders,
drank alcohol more than once per month, used any
illicit drugs or had low mentality were excluded. A
total of 106 subjects conformed to the criteria and were
recruited as the control group [18].
Survey instruments
World Health Organization Questionnaire on 
Quality of Life: Short Form–Taiwan version 
(the WHOQOL-BREF Taiwan version)
The WHOQOL-BREF Taiwan version assessed the
overall rating of QOL (2 items) and four QOL domains,
including physical health (7 items), psychological 
(6 items), social relations (4 items) and environment
(9 items) [28]. The transformed scores of the four QOL
domains ranged from 4 to 20, and Cronbach’s α ranged
from 0.69 to 0.84 in the present study. Higher scores on
the WHOQOL-BREF Taiwan version indicate a higher
perceived QOL in the preceding 2 weeks.
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Subjects underwent a semi-structured interview based
on the 10-item Y-BOCS [29] to evaluate the severity 
of OCD symptoms in the preceding 2 weeks. Every
item was rated on a 0–4 scale (0 = none, 4 = extreme).
Higher total scores of the first five and second five
items indicate more severe obsessions and compul-
sions, respectively. The Cronbach’s α was 0.86 for
obsessions and 0.94 for compulsions in the present
study.
Taiwanese version of the Beck Depression 
Inventory-II (BDI-II)
The BDI-II assesses the severity of depression [30],
with a total score higher than 17 indicates a depres-
sive tendency [31]. The Cronbach’s α of the Taiwanese
version of the BDI-II in the present study was 0.92.
Social Support Scale (SSS)
We used the SSS, as modified by Wang [32] from the
Inventory of Socially Supportive Behavior developed
by Barrera and Sandler [33]. Cronbach’s α for the 
SSS in the present study was 0.95 and the 1-week
test–retest reliability was 0.92 (p < 0.001). Higher 
SSS scores indicate higher levels of perceived social
support.
Questionnaire on Adverse Effects of Medication for
Depression and Anxiety (QAEM-DA)
We developed the QAEM-DA, which contains 16 items,
to evaluate the patients’ perceived adverse effects in-
duced by antidepressants used to treat OCD in the
preceding 2 weeks [34]. The positive items were
summed to represent the total severity of adverse
effects of medication. Cronbach’s α of the QAEM-DA
in the present study was 0.79 and the 1-week test–
retest reliability was 0.91 (p < 0.001). The QAEM-DA
has been used to assess the adverse effects of antide-
pressants in previous studies on patients with panic
disorder [16] or depressive disorders [17] with satis-
factory validity [16].
Social Status Rating Scale (SSRS)
The SSRS classifies subjects’ social status into classes
I–V according to their education level and occupa-
tion [35]. A high category on the SSRS indicates low
social status.
Subject characteristics
We recorded the sex, age, education level and marital
status of participants in the OCD and control groups.
Religious observation, duration of illness, age at onset
of OCD, clinical diagnosis of mood disorders recorded
in medical charts, and type and dose of medication
were also recorded for participants in the OCD group.
Based on the results of the review by Fineberg and
Craig [36], participants were divided into two groups.
Subjects who received 60mg/day of fluoxetine, 60mg/
day of paroxetine, 150mg/day of sertraline, 20mg/day
of escitalopram, 200 mg/day of fluvoxamine, 100 mg/
day of clomipramine, or 300mg/day of venlafaxine, or
more, were classified as the high-dose group, while
subjects who received doses of these antidepressants
lower than those stated above were classified as the
low-dose group.
Protocol and statistical analysis
The protocol was approved by the Institutional Review
Board of Kaohsiung Medical University. Informed
consents were obtained from all subjects before start-
ing the study. A researcher explained the methods to
complete the questionnaires to each participant, and
then the participants completed the questionnaires
by themselves. Participants also underwent a semi-
structured interview based on the Y-BOCS to evaluate
the severity of OCD symptoms in preceding 2 weeks.
Among subjects in the OCD and control groups,
the influences of the diagnosis of OCD on the five
QOL domains on the WHOQOL-BREF Taiwan version
were examined using stepwise multiple linear regres-
sion analyses controlling for sex, age, education level
and marriage. The relationships between the five QOL
domains on the WHOQOL-BREF Taiwan version and
subjects’ sociodemographic data, current severity of
OCD symptoms, BDI-II depression scores, perceived
social support, clinical diagnosis of mood disorders,
the type and doses of medications, and adverse effects
of medications, were analyzed with t tests, analysis
of variance and Pearson’s correlation. Because multi-
ple comparisons were conducted, a two-tailed p value
of < 0.005 was considered statistically significant. 
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The predictive potential of variables that were signifi-
cantly associated with QOL in bivariate analyses was
further examined using forward stepwise multiple
linear regression analysis, and a two-tailed p value of
< 0.05 was considered statistically significant.
RESULTS
The sociodemographic data, course of illness, psy-
chopathology, perceived social support, level of QOL
on the WHOQOL-BREF Taiwan version, and treat-
ment characteristics are shown in Tables 1 and 2.
After controlling for sex, age, education, and marriage,
the OCD group had worse QOL in the general
(β = –0.322, t = –4.097, p < 0.001), physical (β = –0.512,
t=–7.350, p<0.001), psychological (β=–0.290, t=–3.704,
p<0.001) and social relationships (β=–0.191, t=–2.495,
p = 0.014) domains than the control group. However,
no difference was found between the two groups for
the environmental domain (β=0.042, t=0.517, p>0.05).
Tables 3 and 4 present the associations between
the overall rating and the four QOL domains on the
WHOQOL-BREF Taiwan version and subjects’ socio-
demographic data, current severity of OCD symptoms,
BDI-II depression scores, perceived social support,
type and dose of medications, and adverse effects of
medications analyzed with t tests, analysis of variance
and Pearson’s correlation for the OCD group. The re-
sults indicated that QOL was worse in the social rela-
tionship and environment domains for subjects with
low (class V) social status than those with higher social
status (classes I–IV). Participants with significant de-
pression (BDI-II ≥ 17) had worse QOL in the general,
physical, psychological, and environment domains
compared with participants without significant de-
pression (BDI-II <17). Participants who received mood
stabilizers had worse QOL in the psychological, social
Kaohsiung J Med Sci August 2010 • Vol 26 • No 8400
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Table 1. Sociodemographic data, course of illness, psychopathology, perceived social support and the level of quality
of life of OCD patients*
Characteristics With OCD (n = 57) Without OCD (n = 106)
Sociodemographic data
Age (yr) 30.3 ± 12.3 (16–70) 33.8 ± 8.1 (18–50)
Education (yr) 13.1 ± 3.4 (2–19) 12.0 ± 1.1 (9–16)
Sex, male 38 (66.7) 51 (48.1)
Married 13 (22.8) 38 (35.8)
Social status on the SSRS (class V) 33 (57.9) 57 (53.8)
Regular religious observation 25 (43.9) 42 (39.6)
Course of illness
Age at onset (yr) 23.0 ± 8.6 (12–61)
Duration (mo) 89.3 ± 103.6 (3–444)
Psychopathology
Total BDI-II score ≥ 17 34 (59.6)
Obsession on the Y-BOCS 9.6 ± 3.7 (2–20)
Compulsion on the Y-BOCS 8.7 ± 4.7 (0–20)
Perceived social support on the SSS 28.0 ± 9.5 (7–45)
Diagnosis of mood disorders
No 35 (61.4)
Yes 22 (38.6)
QOL on WHOQOL-BREF
General 5.5 ± 1.5 (2–9) 6.5 ± 1.3 (3–10)
Physical 12.8 ± 1.9 (9–17) 70.5 ± 11.9 (38–94)
Psychological 11.3 ± 2.3 (6–17) 54.1 ± 12.3 (25–81)
Social relationship 12.6 ± 3.6 (5–21) 61.7 ± 13.4 (25–94)
Environment 12.3 ± 2.5 (5–18) 51.6 ± 16.1 (19–75)
*Data presented as mean ± standard deviation (range) or n (%). OCD = Obsessive–compulsive disorder; SSRS = Social Status Rating
Scale; BDI-II = Taiwanese version of the Beck Depression Inventory-II; Y-BOCS = Yale-Brown Obsessive–compulsive Scale;
SSS = Social Support Scale; WHOQOL-BREF = World Health Organization Questionnaire on Quality of Life: Short Form–Taiwan
Version; QOL = quality of life.
relationship and environment domains compared with
participants who did not receive mood stabilizers.
Severe obsession and compulsion symptoms and low
social support were significantly associated with poor
QOL in all five domains. Severe adverse effects of med-
ications were significantly associated with poor QOL
in the general, physical, psychological and environ-
ment domains. Higher chlorpromazine equivalents
of antipsychotics were significantly associated with
poor QOL in the social relationship domains.
We further examined the predictive potential of
variables in the OCD group that were significantly
associated with QOL in bivariate analyses using step-
wise multiple linear regression analyses. Total BDI-II
scores ≥ 17 and severe current obsession symptoms
were significantly associated with poor QOL in the
general and physical domains (Table 5). Total BDI-II
scores ≥17 and combined use of mood stabilizers were
significantly associated with poor QOL in the psy-
chological domain. Low social status, perceived low
social support and combined use of mood stabilizers
were significantly associated with poor QOL in the
social relationship domain. Total BDI-II scores ≥ 17,
severe current obsession symptoms, perceived low
social support, perceived severe adverse effects of
medications and combined use of mood stabilizers
were significantly associated with poor QOL in the
environmental domain.
DISCUSSION
This study found that patients with OCD had worse
QOL on the general, physical, psychological and so-
cial relationship domains compared with the control
group, which shows that OCD negatively influenced
the conditions that are essential for maintaining good
QOL in these three domains. A previous study found
that the general domain of the WHOQOL-BREF was
positively correlated with serotonin transporter avail-
ability in male healthy controls [37]. It was speculated
that the scope of global perception of QOL may over-
lap with the daily sense of perceived joy or happiness
[37]. However, no difference in the environmental QOL
domain was found between these two groups. The
results of this study indicate that different domains
of QOL are differently affected by OCD.
The present study found that comorbid depression,
symptoms of obsession, low social status, perceived
lack of social support, adverse effects of medication,
and combined use of mood stabilizers were associated
with poor QOL in some domains on the WHOQOL-
BREF Taiwan version among patients with OCD. The
results indicate that the QOL of patients with OCD is
associated with multiple factors that are specific to
individual subjects and is influenced by interactions
with treatment and the social environment. These re-
sults should encourage clinicians to screen for these
factors and, if present, intervene to improve QOL in
patients with OCD.
Consistent with the results of previous studies
[8,13], the present study found that severe obsession
symptoms and comorbid depression were associated
with poor QOL in patients with OCD. This indicates
that adequate treatment of OCD and the comorbid
depressive symptoms is an important step towards im-
proving QOL. On the other hand, this study also found
that adverse effects of medications predicted poor
QOL in the environment domain. Because OCD has a
chronic course [5], a long-term treatment is necessary
for many patients with OCD. Although several types
Quality of life in obsessive-compulsive disorder
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Table 2. Treatment characteristics*
OCD group (n = 57)
Adverse effects of medications 4.9 ± 3.8 (0–15)
Augmentation of antipsychotic 23 (40.4)
or mood stabilizers
Type of antidepressants
SSRI 42 (73.7)
TCA 3 (5.3)
SNRI 7 (12.2)
SSRI + TCA 5 (8.8)
Antidepressant dose
Low-dose 34 (59.6)
High-dose 23 (40.4)
Types of antipsychotics
No antipsychotic 36 (63.2)
Atypical 12 (21.0)
Typical 9 (15.8)
Combined use of mood stabilizers
No 50 (87.7)
Yes 7 (12.3)
Chlorpromazine equivalents of 39.8 ± 73.0 (0–300)
antipsychotic (mg/day)
*Data presented as mean ± standard deviation (range) or n (%).
OCD = Obsessive–compulsive disorder; SSRI = selective sero-
tonin reuptake inhibitor; TCA= tricyclic antidepressant; SNRI=
serotonin-norepinephrine reuptake inhibitor.
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of antidepressants can improve OCD symptoms, the
antidepressants have different levels of adverse effects
on several organs and systems [38], which may com-
promise patients’ QOL and thus reduce adherence to
treatment [15]. The findings of this study indicate that
clinicians must help patients with OCD to identify
and to manage the adverse effects of therapy. Frequent
discussions with patients may encourage them to con-
tinue treatment and to accept the balance between the
benefits and adverse effects of treatment.
This study also found that combined use of mood
stabilizers was significantly associated with poor
QOL in the psychological, social relationship and
environmental domains. There are several possible
explanations for these associations. First, mood stabi-
lizers may be used for augmentation in patients with
severe OCD symptoms and poor response to routine
antidepressant treatment, and these severe OCD
symptoms compromised their QOL. Second, mood
stabilizers may be used to treat mood symptoms
other than OCD symptoms. Although we did not find
a difference in the level of QOL between those with
and without a clinical diagnosis of mood disorders, it
is possible that a diagnosis of mood disorders was not
recorded in the patients’ charts and any unrecorded
mood disorders may have compromised the level of
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Table 4. Pearson’s correlations analysis (r) between quality of life on the World Health Organization Questionnaire on
Quality of Life: Short Form–Taiwan Version and sociodemographic and treatment characteristics, course of illness,
psychopathology, and perceived social support
General Physical Psychological
Social 
Environment
relationships
Age −0.13 0.04 −0.05 0.02 0.03
Education 0.04 −0.19 −0.01 0.09 −0.10
Onset age of illness −0.10 −0.02 0.01 0.11 −0.02
Duration of illness −0.19 0.05 −0.10 −0.10 0.02
Obsession on the Y-BOCS −0.59† −0.58† −0.37* −0.27* −0.48†
Compulsion on the Y-BOCS −0.51† −0.55† −0.43† −0.31* −0.41†
Perceived social support 0.29* 0.20* 0.16* 0.36* 0.32*
Adverse effects of medication −0.38* −0.42† −0.36* −0.13 −0.47†
Chlorpromazine equivalents 0.12 0.04 −0.17 −0.31* −0.16
of antipsychotic
*p < 0.005; †p < 0.001. Y-BOCS = Yale-Brown Obsessive–compulsive Scale.
Table 5. Variables associated with quality of life on the World Health Organization Questionnaire on Quality of Life:
Short Form–Taiwan Version in stepwise multiple linear regression
General Physical Psychological
Social 
Environment
relationships
β t β t β t β t β t
BDI-II ≥ 17 –0.261 –2.212* –0.371 –3.257† –0.448 –4.068‡ –0.326 –3.004†
Obsession on the –0.472 –3.995‡ –0.410 –3.593† –0.224 2.027*
Y-BOCS
Social status –0.229 –1.946*
(class V)
Perceived social 0.381 3.394† 0.245 2.385*
support
Adverse effects –0.287 –2.645*
of medication
Combined use of –0.348 –3.162† –0.369 –3.144† –0.396 –4.048‡
mood stabilizers
Adjusted R2 0.385 0.425 0.329 0.341 0.491
F value 18.325‡ 21.675‡ 14.750‡ 10.660‡ 14.485‡
*p < 0.05; †p < 0.01; ‡p < 0.001. BDI-II = Taiwanese version of the Beck Depression Inventory-II; Y-BOCS = Yale-Brown Obsessive–
compulsive Scale.
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QOL. Third, mood stabilizers may have adverse effects
that exert a negative effect on QOL. Because this study
only evaluated the adverse effects of antidepressants,
the association between QOL and the adverse effects
of mood stabilizers needs further study.
Some studies have found that the QOL of some
patients with OCD did not improve even with an im-
provement in OCD symptoms due to medication [14,
39]. This suggests that there are factors other than
OCD symptoms that influence QOL. The findings of
this study indicate that low social support was asso-
ciated with poor QOL in the social relationship and
environment domains in patients with OCD. Of note,
patients with OCD may show dysfunction in the
areas of work inside the home and functioning as a
family unit [7,9], which, ironically, may reduce sup-
port from their families. To enhance family support
and improve patients’ QOL, it may be helpful, with
the patients’ permission, for clinicians to explain the
characteristics of OCD and teach family members the
skills necessary to help patients managing their OCD
symptoms.
This study found that low social status was signif-
icantly associated with poor QOL in the social rela-
tionship domain. Because OCD has a negative impact
on work ability and economic independence [7–9,11],
the social status of patients with OCD may deterio-
rate in the course of illness, leading to impaired QOL.
The WHOQOL-BREF includes domains on life
function critical to health-related QOL [40] and, as 
a generic scale, provides information that is compa-
rable across patient groups and populations with 
different languages and cultures. Meanwhile, the
WHOQOL BREF is a transcultural instrument with
high face and construct validity within the specific
cultural setting [41].
However, our results needed to be interpreted 
in light of several study limitations. First, the cross-
sectional design of this study limited our ability to draw
conclusions about the causal relationship between
QOL and the associated factors. Second, analysis of 
a small sample of patients from mental health clinics
may limit generalizations to other clinical units or
populations. Some patients with OCD may receive
no treatment or even inappropriate treatment. Third,
although we examined a broad range of individual
and environmental factors, some factors that may
affect QOL in patients with OCD remain unmeasured.
For example, the personality or coping style of the
participants and whether they received psychother-
apy were not explicitly assessed in this study. Fourth,
while QOL is an inherently subjective phenomenon,
psychopathology may affect the mental, emotional and
social judgments on which the patients’ responses to
the QOL instruments are based [42]. No information
from family members, friends or professionals was
used to confirm the participants’ self-evaluation of
the level of QOL in this study. Fifth, the psychological
domain of the WHOQOL-BREF contains an item that
inquires about negative feelings, including anxiety. For
patients with OCD, it is difficult to find out whether 
a specific score on the psychological domain is due to
a high level of anxiety or to poor QOL [43]. Several
items of the WHOQOL-BREF inquire about depressive
symptoms, which increases the association between
QOL and total BDI-II scores.
In conclusion, the present study found that multi-
ple factors, including adverse effects of medication,
type of medication, social support, severity of obses-
sion and depressive symptoms, and social status were
associated with QOL in patients with OCD. The re-
sults should encourage clinicians to screen for these
factors and, if present, intervene to improve the QOL
in patients with OCD.
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強迫症個案的生活品質是進行臨床照護時的重要指標。本研究的目的在於比較具有和
沒有強迫症診斷者生活品質的差異，並探討強迫症患者中生活品質和社會人口學資
料、疾病病程、精神病理、社會支持和接受的治療之間的關連性。本研究以台灣簡明
版世界衛生組織生活品質問卷，比較 57 位強迫症患者和 106 位無強迫症診斷的對照
組個案之生活品質高低，同時調查強迫症患者的生活品質之相關因子為何。結果顯
示：強迫症組個案在整體、生理、心理、社會關係等生活品質分項目皆比對照組個案
較不佳，但在環境分項目上則無顯著差異。有多重因子與強迫症患者的生活品質高低
具相關性，包括合併顯著憂鬱、強迫思考症狀較嚴重、感受到的社會支持程度較低、
接受藥物治療所帶來的副作用較嚴重、合併情緒穩定劑治療、低社經階層等。由本研
究結果可知：強迫症患者的生活品質與個案的本身狀況、接受的治療和所處的社會環
境皆有相關。
關鍵詞：憂鬱，強迫症，生活品質，社會支持
（高雄醫誌 2010;26:397–407）
